Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

Phase 2

Not yet recruiting

• Conditions: Lymphoma, Non-Hodgkin
• Interventions: Biological: Cytokine-induced killer cells (CIK)

• Registration Number: NCT02497898
• Lead Sponsor: The First People's Hospital of Changzhou

Brief Summary

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed Description

Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.

Study Timeline

• Status Verified: 2015-06
• Study First Submitted: 2015-06-29
• Study Start: 2015-07
• Study First Submitted QC: 2015-07-12
• Last Update Submitted: 2015-07-12
• Study First Posted: 2015-07-15
• Last Update Posted: 2015-07-15
• Primary Completion: 2038-07
• Study Completion: 2040-07

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy

Read More

Exclusion Criteria

• patients refuse the therapy or have no tolerance for the therapy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CIK regimen	Cytokine-induced killer cells (CIK)	Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.

Primary Outcome Measures

Name	Time	Method
Progression-Free-Survival (PFS)	1 month

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	1 month